Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Xingang Pharmaceutical Co., Ltd., commonly referred to as Xingang Pharma, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 2001, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of generic drugs and active pharmaceutical ingredients (APIs).
With a strong operational presence across Asia and expanding into global markets, Xingang Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of medications that cater to various therapeutic areas, setting them apart through rigorous quality control and adherence to international standards.
Xingang Pharma has achieved notable milestones, positioning itself as a trusted name in the industry, and continues to enhance its market presence through strategic partnerships and a focus on research and development.
13
DitchCarbon score
-9 vs industry average
Xingang Pharmaceutical’s score of 13 is lower than 32% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Xingang Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very High
Health Services is among the most carbon-intensive industries
Industry performance
0.263
20182025
The Health Services industry has reduced its overall emissions by 23% since 2018
Reported emissions
No reported emissions data is available for Xingang Pharmaceutical yet.
Xingang Pharmaceutical's reported carbon emissions
Xingang Pharmaceutical, headquartered in China (CN), currently does not have available carbon emissions data for the most recent year. As a result, there are no specific figures regarding their total emissions or breakdowns by Scope 1, Scope 2, or Scope 3. Furthermore, the company has not outlined any reduction targets or climate commitments, nor does it appear to be part of any recognised climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP).
In the absence of specific emissions data and reduction initiatives, it is important to note that the pharmaceutical industry is increasingly focusing on sustainability and reducing carbon footprints. Companies in this sector are often encouraged to adopt comprehensive climate strategies to mitigate their environmental impact.
Assessing Xingang Pharmaceutical as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Xingang Pharmaceutical and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Xingang Pharmaceutical’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Xingang Pharmaceutical yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Xingang Pharmaceutical yet.
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more